Pharmaceuticals & Therapeutics

New F1 hybrid cannabis seeds deliver unprecedented yields and uniformity, potentially transforming the industry from large-scale farms to home growers.

Quanterix has submitted a multi-biomarker blood test to the FDA, a move that could revolutionize early Alzheimer's diagnosis and patient care.

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

A new report reveals a major shift in hospital spending, with tech and infrastructure costs now rising faster than drugs for the first time in a decade.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

Celanese completes a key divestiture to tackle its massive debt, while buyer Element Solutions bolsters its high-growth electronics portfolio.

Palomar Holdings finalizes its Gray Surety acquisition, backed by a new $450M credit facility, in a bold strategic move to challenge specialty insurance leaders.

A major investment from Ares and DaVita will help Elara Caring expand in-home care, launching a new model for chronic kidney disease patients.

Beyond M&A, ACROBiosystems' bioSeedin summit redefines growth, connecting global capital with biotech innovation in a new era of strategic partnerships.

A C$20M investment validates Corus's unique doctor-led model, fueling a major expansion across the booming North American orthodontic market.

As AI systems deny healthcare claims at alarming rates, experts argue that human oversight is the only safeguard for both patients and payors.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

Serenity Mental Health Centers expands its ketamine therapy in Florida, offering rapid relief for depression but raising questions about cost and oversight.

MAPS and Columbia University launch a landmark study into MDMA-assisted couples therapy, seeking to turn decades of underground practice into a safe future.

Devonian appoints veteran CFO Dennis Turpin and corrects stock options, signaling a strategic shift as it aims to overcome financial hurdles and advance its pipeline.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

Mwyngil Therapeutics starts clinical trials for a novel brain-penetrating drug, aiming to tackle neuroinflammation at its source in MS and Parkinson's.